NCT07481747: Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
- State
- Under way
- Phase
- Phase 3
- People
- 2,539 planned
- Started
- 2 Feb 2026
- Primary completion
- 14 Feb 2027
- Arms
- Arm 1: Tirzepatide 5 mg once weekly + lifestyle intervention, Arm 2: Tirzepatide 10 mg once weekly + lifestyle intervention, Arm 3: Tirzepatide 15 mg once weekly + lifestyle intervention, Arm 4: Placebo once weekly + lifestyle intervention
- Results
- None posted
- 2 Feb 2026: Trial started
- 19 Mar 2026: Trial registered